Your account is not claimed yet. You can sign up with ORCID to claim your account.

Angel Jonathan Ruiz-Moreno (Angel J Ruiz-Moreno)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2021
Publications (10 Years): 4

Top Topics

Respiratory Syndrome Coronavirus

Hyaluronic Acid

Breast Cancer Cells

Top Venues

RSC medicinal chemistry

Drug design, development and therapy

Pharmaceuticals (Basel, Switzerland)

Molecules (Basel, Switzerland)

University of Groningen (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

University of Groningen

Netherlands

PHD :: Drug Design

Publications

Luis Córdova-Bahena, Axel A Sánchez-Álvarez, Angel Jonathan Ruiz-Moreno, Marco Antonio Velasco Velazquez
Repositioning of Etravirine as a Potential CK1ε Inhibitor by Virtual Screening. Pharmaceuticals (Basel, Switzerland) 15 (1) (2021)
Angel Jonathan Ruiz-Moreno, Atilio Reyes Romero, Alexander Dömling, Marco Antonio Velasco Velazquez
In Silico Design and Selection of New Tetrahydroisoquinoline-Based CD44 Antagonist Candidates. Molecules (Basel, Switzerland) 26 (7) (2021)
Inés Velázquez-Quesada, Angel Jonathan Ruiz-Moreno, Diana Casique-Aguirre, Charmina Aguirre-Alvarado, Fabiola Cortés-Mendoza, Marisol de la Fuente-Granada, Carlos García-Pérez, Sonia Mayra Pérez-Tapia, Aliesha González-Arenas, Aldo Segura-Cabrera, Marco Antonio Velasco Velazquez
Pranlukast Antagonizes CD49f and Reduces Stemness in Triple-Negative Breast Cancer Cells. Drug design, development and therapy 14 (2020)
Rick Oerlemans, Angel Jonathan Ruiz-Moreno, Yingying Cong, Nilima Dinesh Kumar, Marco A Velasco-Velazquez, Constantinos G Neochoritis, Jolanda Smith, Fulvio Reggiori, Matthew R Groves, Alexander S S Dömling
Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics. RSC medicinal chemistry 12 (3) (2020)